Next Article in Journal
Effects of Neuropeptides and Mechanical Loading on Bone Cell Resorption in Vitro
Next Article in Special Issue
Comparative Pulmonary Toxicity of Two Ceria Nanoparticles with the Same Primary Size
Previous Article in Journal
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Previous Article in Special Issue
Toxicological Assessment of Inhaled Nanoparticles: Role of in Vivo, ex Vivo, in Vitro, and in Silico Studies
Int. J. Mol. Sci. 2014, 15(4), 5852-5873; doi:10.3390/ijms15045852

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Institute for Pharmaceutical Technology, TU Braunschweig, Mendelssohnstr. 1, 38106 Braunschweig, Germany
* Author to whom correspondence should be addressed.
Received: 22 January 2014 / Revised: 28 March 2014 / Accepted: 28 March 2014 / Published: 8 April 2014
(This article belongs to the Special Issue Nanotoxicology and Lung Diseases)
View Full-Text   |   Download PDF [377 KB, uploaded 19 June 2014]   |   Browse Figures


Colloidal drug delivery systems have been extensively investigated as drug carriers for the application of different drugs via different routes of administration. Systems, such as solid lipid nanoparticles, polymeric nanoparticles and liposomes, have been investigated for a long time for the treatment of various lung diseases. The pulmonary route, owing to a noninvasive method of drug administration, for both local and systemic delivery of an active pharmaceutical ingredient (API) forms an ideal environment for APIs acting on pulmonary diseases and disorders. Additionally, this route offers many advantages, such as a high surface area with rapid absorption due to high vascularization and circumvention of the first pass effect. Aerosolization or inhalation of colloidal systems is currently being extensively studied and has huge potential for targeted drug delivery in the treatment of various diseases. Furthermore, the surfactant-associated proteins present at the interface enhance the effect of these formulations by decreasing the surface tension and allowing the maximum effect. The most challenging part of developing a colloidal system for nebulization is to maintain the critical physicochemical parameters for successful inhalation. The following review focuses on the current status of different colloidal systems available for the treatment of various lung disorders along with their characterization. Additionally, different in vitro, ex vivo and in vivo cell models developed for the testing of these systems with studies involving cell culture analysis are also discussed.
Keywords: nanoparticles; SLN; toxicity; lung cell models; aerosol; nebulization; lung disease nanoparticles; SLN; toxicity; lung cell models; aerosol; nebulization; lung disease
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Paranjpe, M.; Müller-Goymann, C.C. Nanoparticle-Mediated Pulmonary Drug Delivery: A Review. Int. J. Mol. Sci. 2014, 15, 5852-5873.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert